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Baboons (Papio anubis) receiving a lethal intravenous infusion with live Escherichia coli were
pretreated with either a 55-kDa tumor necrosis factor (TNF) receptor–IgG fusion protein
(TNFR55:IgG) (n 4, 4.6 mg/kg) or placebo (n 4). Neutralization of TNF activity in TNFR55:IgG-
treated animals was associated with a complete prevention of mortality and a strong attenuation
of coagulation activation as reflected by the plasma concentrations of thrombin–antithrombin III
complexes (P  .05). Activation of fibrinolysis was not influenced by TNFR55:IgG (plasma tissue-
type plasminogen activator and plasmin–a2-antiplasmin complexes), whereas TNFR55:IgG did
inhibit the release of plasminogen activator inhibitor type I (P  .05). Furthermore, TNFR55:IgG
inhibited neutrophil degranulation (plasma levels of elastase–a1-antitrypsin complexes, P  .05)
and modestly reduced release of secretory phospholipase A2. These data suggest that endogenous
TNF contributes to activation of coagulation, but not to stimulation of fibrinolysis, during severe
bacteremia.
Tumor necrosis factor-a (TNF) is considered to be a key lethality [5–7]. Similarly, anti-TNF did not influence coagula-
tion activation during nonlethal endotoxemia in chimpanzeesmediator in the pathogenesis of sepsis syndrome. TNF is re-
leased into the circulation early after intravenous bacterial chal- [8]. By contrast, anti-TNF completely prevented the fibrinolytic
response to nonlethal endotoxemia [8], whereas in the lethallenges in animals, and neutralization of endogenous TNF pre-
vents lethality in these acute models [1]. The role of TNF models fibrinolysis was not investigated.
Recently, the capacity of a 55-kDa TNF receptor–IgG fusionin disturbances of the hemostatic mechanism during systemic
infection is less clear. Sepsis- or endotoxin-induced activation protein (TNFR55:IgG) to effectively neutralize TNF activity
and to strongly reduce lethality in baboons infused with a lethalof the coagulation system is driven by the tissue factor–medi-
ated extrinsic pathway [2]. TNF potently up-regulates tissue dose of live Escherichia coli was reported [9]. Interestingly,
treatment with TNFR55:IgG attenuated fibrinogen consump-factor expression on endothelial and mononuclear cells, sug-
gesting a role for this cytokine in coagulation activation [1, tion and the increases in prothrombin and partial thromboplas-
tin times caused by the bacteremia. These findings prompted2]. In accord, intravenous injection of recombinant TNF into
humans or baboons induced activation of the common pathway us to study in more detail the effect of TNFR:IgG on the
activation of coagulation and fibrinolysis.of the coagulation system [3, 4]. However, treatment of ba-
boons with severe bacteremia or endotoxemia with a neutraliz-
ing anti-TNF monoclonal antibody did not result in a noticeable
Methodseffect on activation of the coagulation system, in spite of the
fact that such treatment afforded significant protection against
Study design. The present study was performed simultaneously
with a previously reported investigation [9]. Details of the animal
study have been reported elsewhere [9]. Briefly, baboons (Papio
anubis) (10–14 kg) were challenged with E. coli with or without
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Assays. All assays were performed in heparinized plasma sam-
ples and were described in detail previously [4, 10]. Coagulation
activation was determined by measuring thrombin–antithrombin
III (TAT) complexes by ELISA. Fibrinolytic activation was moni-
tored by measurements of tissue type plasminogen activator (tPA)
by ELISA, plasminogen activator inhibitor type I (PAI-1) by
ELISA, and plasmin–a2-antiplasmin (PAP) complexes by RIA.
Levels of PAP complexes are expressed as percentage of the level
present in normal baboon plasma in which a maximal amount of
PAP complexes was generated by a 1-h incubation with an equal
volume of urokinase (50 mg/mL) in the presence of 0.4 M methyl-
amine. Neutrophil degranulation was determined by measurement
of the plasma concentrations of elastase–a1-antitrypsin complexes
by RIA. Secretory phospholipase A2 (sPLA2) was measured with
an ELISA.
Statistical analysis. All values are expressed as mean { SE.
Differences within groups were tested by repeated-measures analy-
sis of variance. Differences between groups were tested by re-
peated-measures analysis of variance (interaction between treat-
ment and time). P values are therefore derived from analyses in
which data from all time points were included. P  .05 was
considered to represent a significant difference.
Results
In the previously reported study, treatment with
TNFR55:IgG had been found to completely neutralize TNF
activity throughout the observation period and to significantly
attenuate the severe hypotensive response and lethality ob-
served in the animals infused with E. coli [9]. Three of four
baboons pretreated with placebo had died, after 6, 30, and 36
h, respectively, while all baboons treated with TNFR55:IgG
survived.
The infusion of E. coli was associated with a strong activa-
tion of the common pathway of the coagulation system, as
reflected by a sustained rise in the plasma concentrations of
TAT complexes, peaking after 6 h (959 { 296 ng/mL; P .05
vs. time) (figure 1). This coagulation response was significantly
blunted by treatment with TNFR55:IgG. Peak levels of TAT
complexes in TNFR55:IgG-treated animals were 322 { 90
ng/mL (P  .05 vs. placebo). Bacteremia also induced a
marked activation of the fibrinolytic system, as indicated by
increases in the plasma concentrations of tPA (peak of 12.9 {
2.2 ng/mL after 8 h; P  .05 vs. time), PAI-1 (peak of 3669
{ 1298 ng/mL after 8 h; P  .05), and PAP complexes (peak
of 0.68% { 0.32% after 4 h; P  .05) (figure 1). Treatment
with TNFR55:IgG had no influence on the rise in tPA levels but
significantly attenuated the release of PAI-1 during bacteremia.
Peak PAI-1 levels in TNFR55:IgG-infused baboons were 1095
{ 314 ng/mL (P .05 vs. placebo). The plasma concentrations
Figure 1. Effect of pretreatment with 55-kDa TNF receptor–IgG fusionof PAP complexes tended to be higher in TNFR55:IgG-treated
protein (TNFR55:IgG) on activation of coagulation and fibrinolysis. Dataanimals (peak of 0.85% { 0.32% after 4 h), but the difference
are mean ({SE) plasma concentrations of thrombin-antithrombin III
compared with control animals did not reach statistical signifi- (TAT) complexes, tissue-type plasminogen activator (tPA), plasminogen
cance. activator inhibitor type I (PAI-1), and plasmin–a2-antiplasmin (PAP) com-
plexes after infusion of Escherichia coli in baboons pretreated with eitherAs reported earlier [9], bacteremia was associated with a
TNFR55:IgG (n  4, l) or placebo (n  4, s). P indicates differencesustained neutrocytopenia, which was partially reversed by
between groups by analysis of variance. NS  nonsignificant.
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protein results in an attenuated procoagulant response, as re-
flected by inhibition of release of TAT complexes, in the ab-
sence of an effect on activation of fibrinolysis. This result is
in line with the previously reported inhibition of more rough
measures of coagulation activation, such as fibrinogen con-
sumption and prolongation of prothrombin and partial thrombo-
plastin times [9]. However, it should be noted that, thus far,
studies in which endogenous TNF was neutralized in primates
with either lethal or sublethal bacteremia or endotoxemia did
not reveal any effect on activation of the coagulation system
[5–8], while anti-TNF did abrogate the fibrinolytic response
to low-dose endotoxin in chimpanzees [8]. We do not have an
explanation for the apparent discrepancy of the present results
with those from earlier studies, other than that the compound
used to neutralize TNF activity, a dimeric 55-kDa TNF recep-
tor–IgG fusion protein (which also has affinity for lympho-
toxin), was different.
We consider it unlikely that our results are influenced by
less-than-complete neutralization of TNF. Plasma TNF activity
remained completely neutralized (as determined by the highly
sensitive WEHI cytotoxicity assay) in animals treated with
TNFR55:IgG throughout the entire observation period [9]. In
fact, even lower doses of TNFR55:IgG than used in this study
were able to completely neutralize TNF activity [9]. Further,
TNFR55:IgG has been found to form stable complexes with
TNF, in which aspect it differs from a similar IgG fusion
protein containing a dimeric p75 TNF receptor [11]. Further,
Figure 2. Effect of 55-kDa TNF receptor–IgG fusion protein we consider it unlikely that the large spread in the levels of PAP
(TNFR55:IgG) on neutrophil degranulation and secretory phospholi-
complexes had an important influence on our main conclusionpase A2 (sPLA2) release. Data are mean ({SE) plasma concentrations
regarding an unaltered fibrinolytic response in animals treatedof elastase–a1-antitrypsin complexes and sPLA2 after infusion of
with TNFR55:IgG. Indeed, in our previous study of low-gradeEscherichia coli in baboons pretreated with either TNFR55:IgG (n
 4, l) or placebo (n  4, s). P indicates difference between groups endotoxemia in chimpanzees, anti-TNF completely prevented
by analysis of variance. NS  nonsignificant. any rise in tPA and PAP complexes [8, 12], while in the present
study, the levels of PAP complexes even tended to be higher
in animals in which TNF was effectively neutralized.
TNFR55:IgG. Infusion of E. coli also resulted in degranulation Excessive activation of neutrophils may contribute in an
of neutrophilic granulocytes, as reflected by an increase in the important way to tissue injury in sepsis [13]. The plasma con-
plasma levels of elastase–a1-antitrypsin complexes, maximal centrations of elastase–a1-antitrypsin complexes have been
levels being measured at the end of the study period at 8 h used as indicators of neutrophil degranulation in vivo and corre-
(1234{ 153 ng/mL; P .05 vs. time) (figure 2). TNFR55:IgG late with mortality rates in patients with sepsis [13]. TNF has
significantly inhibited this response, with elastase–a1-antitryp- been found to trigger neutrophil degranulation in vitro [1] and
sin complexes reaching an approximately constant level at in humans and baboons in vivo [4, 14]. The present results
500 ng/mL from 1 to 8 h (P  .05 vs. placebo). E. coli that TNFR55:IgG reduced the release of elastase in bacteremic
bacteremia further caused a rise in the plasma concentrations baboons are in line with a similar inhibition of elastase release
of sPLA2, the highest levels being measured at the end of the by an anti-TNF antibody in endotoxemic chimpanzees [8] and
observation period (8 h: 4217 { 2081 ng/mL; P  .05 vs. therefore extend the role of TNF in neutrophil degranulation
time) (figure 2). Although TNFR55:IgG reduced sPLA2 release to lethal bacteremia.
(8 h: 1845 { 1284 ng/mL), the difference with control baboons sPLA2 is a regulatory enzyme controlling the synthesis of
did not reach statistical significance because of a large interindi- eicosanoids and platelet-activating factor, which has been im-
vidual variation. plicated in the pathogenesis of tissue injury associated with
sepsis. Injection of TNF into baboons elicited a rapid release
of sPLA2 [4]. Pretreatment with TNFR55:IgG was associatedDiscussion
with a modest, nonsignificant inhibition of sPLA2 release, sug-
gesting that TNF is not a critical mediator of this response inThe main finding of this study is that pretreatment of baboons
with severe E. coli bacteremia with a TNF receptor–IgG fusion sepsis. Similarly, infusion of an anti-TNF antibody also mod-
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4. Van der Poll T, Jansen PM, van Zee KJ, et al. Tumor necrosis factor aestly reduced sPLA2 secretion in an earlier study with bacter-
induces activation of coagulation and fibrinolysis in baboons throughemic baboons [15].
an exclusive effect on the p55 receptor. Blood 1996;88:922–7.
One control animal had died at the time the last blood sample 5. Hinshaw LB, Tekamp-Olson P, Chang ACK, et al. Survival of primates
was taken (after 8 h). The lack of this sample is unlikely to in LD100 septic shock following therapy with antibody to tumor necro-
sis factor (TNFa). Circ Shock 1990;30:279–92.influence the results, since plasma concentrations of PAI-1,
6. Hinshaw LB, Emerson TE, Taylor FB Jr, et al. Lethal Staphylococcuselastase–a1-antitrypsin complexes, and sPLA2 were higher in
aureus–induced shock in primates: prevention of death with anti-TNFmore ill animals, and thus the availability of an 8-h sample from
antibody. J Trauma 1992;33:568–73.
the baboon that died early would likely have made differences 7. Stevens DL, Bryant AE, Hackett SP, et al. Group A streptococcal bacter-
between control animals and animals treated with TNFR55:IgG emia: the role of tumor necrosis factor in shock and organ failure. J
Infect Dis 1996;173:619–26.more pronounced.
8. Van der Poll T, Levi M, Van Deventer SJH, et al. Differential effects ofSevere E. coli bacteremia in baboons may be a useful model
anti-tumor necrosis factor monoclonal antibodies on systemic inflam-
to study pathogenetic mechanisms underlying inflammatory re-
matory responses in experimental endotoxemia in chimpanzees. Blood
sponses during fulminant septic shock. We herein demonstrate 1994;83:446–51.
that neutralization of endogenous TNF by pretreatment with a 9. Van Zee KJ, Moldawer LL, Oldenburg HSA, et al. Protection against
lethal Escherichia coli bacteremia in baboons (Papio anubis) by pre-55-kDa TNF receptor–IgG fusion protein not only prevents
treatment with a 55-kDa TNF receptor (CD120a)–Ig fusion protein, Rolethality but also significantly attenuates coagulation activation
45-2081. J Immunol 1996;156:2221–30.
while not influencing fibrinolysis. Compared with earlier find- 10. Jansen PM, Boermeester MA, Fischer E, et al. Contribution of interleukin-
ings in primates with mild endotoxemia, revealing unaltered 1 to activation of coagulation and fibrinolysis, to neutrophil degranula-
tion and the release of sPLA2 in sepsis. Studies in non-human primatescoagulation activation and inhibited fibrinolytic activation in
following interleukin-1a administration and during lethal bacteremia.animals treated with an anti-TNF antibody [8], these data illus-
Blood 1995;86:1027–34.trate the divergence of various sepsis models, which depend
11. Evans TJ, Moyes D, Carpenter A, et al. Protective effect of 55- but not
on the severity and the time course of toxicity evoked by the 75-kD soluble tumor necrosis factor receptor–immunoglobulin G fusion
bacterial insult, and also point to the difference in the effects proteins in an animal model of Gram-negative sepsis. J Exp Med 1994;
180:2173–9.exerted by the various anti-TNF agents used in such studies.
12. Biemond BJ, Levi M, ten Cate H, et al. Plasminogen activator and PAI-
1 release during experimental endotoxemia in chimpanzees: effects of
various interventions in the cytokine and coagulation cascades. Clin Sci
References
1995;88:587–94.
1. Van der Poll T, Lowry SF. Tumor necrosis factor in sepsis: mediator of 13. Nuijens JH, Abbink JJ, Wachtfogel YT, et al. Plasma elastase–a1-antitryp-
multiple organ failure or essential part of host defense? Shock 1995;3: sin and lactoferrin in sepsis: evidence for neutrophils as mediators of
1–12. fatal sepsis. J Lab Clin Med 1992;19:159–68.
2. Levi M, ten Cate H, van der Poll T, van Deventer SJH. New insights in 14. Van der Poll T, van Deventer SJH, Hack CE, et al. Effects on leukocytes
the pathogenesis of disseminated intravascular coagulation in sepsis. following injection of tumor necrosis factor into healthy humans. Blood
JAMA 1993;270:975–9. 1992;79:693–8.
3. Van der Poll T, Bu¨ller HR, Ten Cate H, et al. Activation of coagulation 15. Redl H, Schlag G, Schiesser A, Davies J. Tumor necrosis factor is a
after administration of tumor necrosis factor to normal subjects. N Engl mediator of phospholipase release during bacteremia in baboons. Am J
Physiol 1993;264:H2119–23.J Med 1990;322:1622–7.
/ 9d2b$$jy42 05-28-97 07:49:24 jinfal UC: J Infect
